VITARNA

Vitarna is a pre-clinical stage biotechnology company dedicated to pioneering the oral delivery of RNA-based medicines. Leveraging proprietary lipid nanoparticle (LNP) technology, the company aims to transform how mRNA and siRNA therapies are administered, moving from traditional injections to convenient oral formats. Vitarna's platform is designed to protect RNA cargo from the harsh environment of the gastrointestinal tract while ensuring efficient uptake into target cells. The company was founded by a team of industry veterans and academic leaders with deep expertise in nucleic acid delivery and nanoparticle engineering. Their mission is to broaden the therapeutic potential of RNA by making it accessible for a wider range of chronic and acute conditions, including gastrointestinal and systemic metabolic diseases.